2024-03-22 08:23:40
On March 20, SynAct Pharma convened an Extraordinary General Meeting, resulting in a new composition of the Board of Directors. Additionally, Jeppe Øvlesen is regaining the position as CEO with the aim to get the company "back on track". BioStock reached out to Jeppe and CSO Thomas Jonassen to learn more about the changes and strategic direction.
Read the full article at biostock.se (https://www.biostock.se/en/):
https://www.biostock.se/en/2024/03/synacts-new-ceo-i-am-hitting-the-ground-running/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se